Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.

Centogene, a Germany-based rare disease diagnosis technology spinout from University of Rostock, is considering going public in an initial public offering on the Nasdaq stock exchange, Reuters reported on Friday. The transaction could reportedly take place as soon as the second or third quarter of 2019. Founded in 2006, Centogene has created a diagnostics system…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.